Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalized Targeted Preparative Regimen and HSCT in Children with Chemoresistant Acute Leukemia
NCT04000698Phase 3Unknown
- Sponsor
- Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology
- Start
- Oct 2019
- Primary completion
- Jul 2022
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of venetoclax, daratumumab, plerixafor in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), sponsored by Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. Status: unknown.
02
Drugs
venetoclaxdaratumumabplerixafor
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT04000698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04000698.